istock-512543170-agreement
Choreograph / iStockphoto.com
20 February 2017Americas

Novartis in $1bn cardiovascular deal with Ionis and Akcea

Novartis has finalised its agreement with biopharmaceutical company Ionis Pharmaceuticals and its wholly-owned subsidiary Akcea Therapeutics to develop and commercialise therapies for cardiovascular disorders.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
20 November 2020   US cardiovascular therapies company Medicure has settled a patent infringement dispute with rival Nexus Pharmaceuticals.

More on this story

Americas
20 November 2020   US cardiovascular therapies company Medicure has settled a patent infringement dispute with rival Nexus Pharmaceuticals.

More on this story

Americas
20 November 2020   US cardiovascular therapies company Medicure has settled a patent infringement dispute with rival Nexus Pharmaceuticals.